- UltraGreen is a global fluorescence-guided surgery (FGS) powerhouse with a dominant indocyanine green (ICG) market leadership, extensive distribution network and superior margin profile. Initiate coverage with BUY recommedation.
- - Read this at SGinvestors.io -
Global leader in ICG with superior margins.
- UltraGreen.ai (SGX:ULG) is the worldβs largest supplier of indocyanine green (ICG), commanding 68% of the global vial share and 63% revenue share in 2024 across more than 68 markets (35 registered, 33 under exemption). This is supported by high regulatory barriers and entrenched supplier-manufacturer relationships.
- - Read this at SGinvestors.io -
Strong growth engine fuelled by volume expansion and pricing power.
- UltraGreen has delivered robust growth momentum, with operating cash flow surging 33% y-o-y in 1H25 to S$27.6m. Strong 1H25 top-line of US$70m (+20% y-o-y) was driven by rising ICG utilisation and increased global adoption of fluorescence-guided surgery (FGS).
- We forecast 2024-27 revenue and EPS CAGRs of 21% and 22% respectively, supported by higher procedure volumes, expanding APAC penetration, and continued premium pricing.
Beneficiary of strong industry tailwinds in FGS adoption.
- Read more at SGinvestors.io.
John Cheong UOB Kay Hian Research | Heidi Mo UOB Kay Hian Research | Tang Kai Jie UOB Kay Hian Research | https://research.uobkayhian.com/ 2025-12-03
Read also 's most recent report:
2026-05-06 UltraGreen.ai 1Q26 - Broad-based Volume Growth & Continued Expansion.
Previous report by :
2026-05-05 UltraGreen.ai 1Q26 Business Update - Sequential Growth Points To Healthy Underlying Demand.
Price targets by other brokers at UltraGreen Target Prices.
Listing of research reports at UltraGreen Analyst Reports.
Relevant links:
UltraGreen Share Price History,
UltraGreen Announcements,
UltraGreen Dividend Payout Dates & Corporate Actions,
UltraGreen News














